BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Allplex SARS-CoV-2 Assay by Seegene Inc wins BioSpectrum Asia Product of the Year Award 2022

December 6, 2022 | News

A Powerful Performance

Asia has, indeed, become the new hub for potential growth and innovation, with no signs of losing steam. To appreciate the Asian companies and individuals for their commendable performance and achievements during Calendar Year (CY) 2021, BioSpectrum Asia Excellence Awards 2022 ceremony was held at Lavender Ball Room, Hotel Fort Canning in Singapore on December 2, 2022, and Allplex SARS-CoV-2 Assay by Seegene Inc received the BioSpectrum Asia Product of the Year Award 2022.

In 2020 and 2021, South Korea-based Seegene Inc fought relentlessly with the emerging pandemic and developed multiple products for the timely and effective diagnosis of COVID-19 and its variants. Allplex SARS-CoV-2 Assay is one such critical product developed by the company in the form of a multiplex real-time PCR assay to detect 4 target genes of SARS-CoV-2, causing COVID-19, in a single tube.

The assay is designed to detect RdRP, S and N genes specific for SARS-CoV-2, and E gene for all of Sarbecovirus including SARS-CoV-2. It can be applied on Seegene's automated system that enables high throughput testing.

The assay provides results within 2 hours after extraction, with high sensitivity and specificity. The product development is based on Seegene's proprietary MuDT technology, reporting individual Ct value of multiple targets in a single channel. MuDT is the world's first real-time PCR technology that provides individual Ct values for multiple targets. By utilising a change of the fluorescence signals between two different detection temperatures, MuDT enables to provide 'Real' Ct value of each pathogen even in co-infected cases.

The product also confirms zero cross-reactivity with 54 respiratory pathogens including SARS, MERS and SARS-related viruses. With Allplex SARS-CoV-2 Assay, 77 million tests were carried out until October this year, and 330 million tests were done in over 65 countries during the pandemic since 2020.

Seegene was founded in Seoul in 2000 and has subsidiaries in the US, Canada, Germany, Italy, Mexico, Brazil, Colombia and the Middle East. As an in-vitro diagnostics (IVD) company, Seegene has been turning innovative technologies into products through its pioneering R&D activities.

Image caption- L-R- Ravindra Boratkar, Publisher & Managing Editor, BioSpectrum Asia; Christopher Hardesty, Partner, Pureland Global Venture; and Lin Sheng Wong, Chief Executive Officer, Genomax Technologies (business partner of Seegene in Singapore)